Helpful discussion material you can share with your patients
Being diagnosed with adult male hypogonadism due to an associated medical condition can be a confusing time for your patients. They may not understand what testosterone does and the role it plays in their body. That’s why it’s so important they get all the information they need about both their condition and treatment. The 1.62% Treatment Experience has educational material available to help facilitate this discussion.
The presentation below, brought to you by The 1.62% Treatment Experience, can be used to help your patients better understand hypogonadism, due to an associated medical condition, the benefit of AndroGel 1.62%, and the important safety considerations regarding its use.1 You can show the presentation directly from your computer/tablet or send it directly to your patients.
What You Should Know About AndroGel 1.62%
Educate your patients about AndroGel 1.62%, how it works, how to apply it, what to expect, and when to come back.
- AndroGel 1.62% is contraindicated in men with breast cancer or known or suspected prostate cancer, and in women who are or may become pregnant or are breastfeeding, as testosterone may cause fetal harm.
- AndroGel 1.62% is not indicated for use in women.
- Most common adverse reaction of AndroGel 1.62% (incidence ≥5%) is an increase in prostate specific antigen (PSA).